In BV2 microglial cells, esketamine suppressed lipopolysaccharide-induced M1 polarization by selectively acting on the NMDAR2A receptor subtype and activating mTOR and BDNF-TrkB signaling.
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases ORR and ...
A query audit of 26 named KEGG signaling pathways in extracellular-vesicle research found that only three PubMed retrievals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results